Ingredients

With approximately 80 percent of new drugs suffering from poor solubility and bioavailability, understanding solid form is more important than ever.

High-throughput excipient discovery looks set to boost oral bioavailability.

What do trends in small molecule drugs mean for contract manufacturers?

Can hot-melt coating reduced processing times and costs, and improve taste?

John Lambert talks antibody-drug conjugates and his involvement with Kadcyla.

We must overcome the challenges of microparticulates to improve the patient experience.

The industry is shifting towards biopharmaceuticals, but there is still demand for synthetic APIs.

How flow chemistry is opening the way to new forms of portable API synthesis.

How close are we to the real-world implementation of drugs-on-demand technology?

Mark Paxton was appointed CEO of Rx-360 in 2015. Here, he discusses the journey so far